• A Pilot Randomized Controlled Trial of De Novo Belatacept-based Immunosuppression After Lung Transplantation. 

      Huang, Howard J; Schechtman, Kenneth; Askar, Medhat; Bernadt, Cory; Mitter, Brigitte; ... more authors ( Wolters Kluwer Health , 2024 , Article)
      Chronic lung allograft dysfunction (CLAD) is the leading cause of death beyond the first year after lung transplantation. The development of donor-specific antibodies (DSA) is a recognized risk factor for CLAD. Based on ...